ABSTRACT

APIXABAN FORMULATIONS

Compositions comprising crystalline apixaban particles having a D_{90} equal to or less than 89 εm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

Fig. 3